Ding-Kun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ding-Kun Liu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bing Yuan
The Fifth Medical Center of Chinese PLA General Hospital
1 shared publication - Danni Ai
Beijing Institute of Technology
1 shared publication - Feng Duan
Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China
1 shared publication - Jian Yang
Beijing Institute of Technology
1 shared publication - Jiangtao Liu
Faculty of Liver Disease of Chinese PLA General Hospital, The Fifth Medical of Chinese PLA General Hospital, Beijing, China
1 shared publication - Jinghui Dong
Department of Radiology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
1 shared publication
Latest Publications
- Open Access
- 4 December 2024
- Published by Springer Nature in Research Square
Evaluation of response to Targeted therapy and immunotherapy for advanced HCCs: A retrospective, controlled study
Background: To validate the correlation between radiomics extracted from magnetic resonance imaging (MRI) and pathologic alterations in advanced hepatocellular carcinoma (HCC) treated with targeted therapy and immunotherapy, and to compare the accuracy of necrosis evaluation by radiologists and subtraction technology. Methods: Thirty-five patients diagnosed unresectable HCCs (n = 39) who underwent curative resection at two centers after receiving combined treatment with tyrosine kinase inhibitors and programmed death ligand-1 antibodies were included. Using linear regression model to verify the consistency between investigator-based imaging evaluation and three-dimensional (3D) subtraction-based imaging analysis and their capability to distinguish major pathological response (MPR) and pathological complete remission (PCR) were compared using receiver operating characteristic (ROC) curve analysis with pathological outcome as the gold standard.The sensitivity, specificity, and area under the ROC curve (AUC) were compared. Results: 3D subtraction-based imaging analysis suggested a strong correlation with histopathologic alteration (R2 = 0.81) and was superior in classifying MPR or PCR comparing to the use of investigator-based imaging evaluation (area under the receiver operator characteristic curve: MRP, 0.80 vs. 0.52; PCR, 0.69 vs. 0.54). Conclusion: 3D subtraction-based imaging analysis based on tumor characteristics showed a stronger correlation with pathology, and 3D subtraction-based imaging analysis was significantly superior to investigator-based imaging evaluation in classifying MPR or PCR.
- 4 December 2024
- Published by Springer Nature in Research Square
Open AccessEvaluation of response to Targeted therapy and immunotherapy for advanced HCCs: A retrospective, controlled study
Background: To validate the correlation between radiomics extracted from magnetic resonance imaging (MRI) and pathologic alterations in advanced hepatocellular carcinoma (HCC) treated with targeted therapy and immunotherapy, and to compare the accuracy of necrosis evaluation by radiologists and subtraction technology. Methods: Thirty-five patients diagnosed unresectable HCCs (n = 39) who underwent curative resection at two centers after receiving combined treatment with tyrosine kinase inhibitors and programmed death ligand-1 antibodies were included. Using linear regression model to verify the consistency between investigator-based imaging evaluation and three-dimensional (3D) subtraction-based imaging analysis and their capability to distinguish major pathological response (MPR) and pathological complete remission (PCR) were compared using receiver operating characteristic (ROC) curve analysis with pathological outcome as the gold standard.The sensitivity, specificity, and area under the ROC curve (AUC) were compared. Results: 3D subtraction-based imaging analysis suggested a strong correlation with histopathologic alteration (R2 = 0.81) and was superior in classifying MPR or PCR comparing to the use of investigator-based imaging evaluation (area under the receiver operator characteristic curve: MRP, 0.80 vs. 0.52; PCR, 0.69 vs. 0.54). Conclusion: 3D subtraction-based imaging analysis based on tumor characteristics showed a stronger correlation with pathology, and 3D subtraction-based imaging analysis was significantly superior to investigator-based imaging evaluation in classifying MPR or PCR.